Efavirenz (HIV Drug) case: Bristol (BMS) won over Mylan Pharma

Bristol Meyers Squibb (BMS), manufacturers of Efavirenz (patented drug for HIV) won over the companies named Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd. that made generic version of Efavirenz that is Sustiva. The companies filed an application in court for the permission to manufacture and sell Sustiva before the patent granted for Efavirenz …

Pharmaceutical Companies shift from Small Molecule Drugs to Biotech Drugs

Recently, the Tufts University’s Center for the Study of Drug Development (CSDD) released an interesting report revealing the dramatic shift of pharmaceutical companies from manufacturing small molecule drugs to a large number of biotechnology drugs. The report shows that in 2001, the biotech products worldwide accounted for only 7% of the revenue …

Important Drug Patents to Expire in 2014 for Generic Production

Year 2014 would be a big loss year for the Pharma companies because of the expiry of patents granted for some of the major medicines. It is estimated that due to the loss of IP protection, sales worth $34 billion is under danger which is very high compared to $28 billion loss faced this year that is in 2013, though the loss would appear less when compared …

Unaffordable Life Saving Drug (Linezolid by Pfizer) Leaves TB Patients Struggling in South Africa

South Africa could not keep up with the treatment for Drug resistant Tuberculosis (TB), which has affected thousands of people in the country. Many of the sufferers would die and the death would be horrible and slow. Not only this, survivors would be struggling with many side effects like loss of hearing and would be requiring pills and injections daily. …

Indian Pharma Landscape: Growing Presence in International Market

Indian pharmaceutical companies have increased their expenditure in their research and development section by 19.7%. The purpose of this increment is not to discover new drugs but to create more cost effective generic drugs. More investment may make them a good competitor for patent grant against the innovators. It was seen that even after increasing …